CureVac NV Total Liabilities
CureVac NV total liabilities. Based on the latest financial reports, CureVac NV (5CV) has total liabilities worth €267.39 Million EUR (≈ $312.61 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CureVac NV liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of CureVac NV (2018–2024)
Total liabilities of CureVac NV from 2018 to 2024. This chart illustrates how CureVac NV's total liabilities have evolved over time, based on quarterly financial data.
CureVac NV Competitors by Total Liabilities
The table below lists competitors of CureVac NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Japfa Comfeed Indonesia Tbk
JK:JPFA
|
Indonesia | Rp23.81 Trillion |
|
Neurones
PA:NRO
|
France | €284.16 Million |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
USA | $32.20 Million |
|
Generation Development Group Ltd
AU:GDG
|
Australia | AU$5.58 Billion |
|
Suzhou Huaya Intelligence Technology Co Ltd
SHE:003043
|
China | CN¥1.02 Billion |
|
CH. Karnchang PCL
BK:CK
|
Thailand | ฿87.98 Billion |
|
Shanghai Prisemi Electronics Co Ltd
SHG:688230
|
China | CN¥58.91 Million |
|
BlackRock Credit Allocation Income Trust
NYSE:BTZ
|
USA | $711.43 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down CureVac NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CureVac NV assets under control.
Liquidity & Leverage Metrics
CureVac NV Total Liabilities Ratios Explained
CureVac NV total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CureVac NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CureVac NV (2018–2024)
The table below shows the annual total liabilities of CureVac NV from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €106.22 Million ≈ $124.18 Million |
-60.85% |
| 2023-12-31 | €271.31 Million ≈ $317.19 Million |
-17.09% |
| 2022-12-31 | €327.22 Million ≈ $382.55 Million |
-30.34% |
| 2021-12-31 | €469.77 Million ≈ $549.21 Million |
-41.28% |
| 2020-12-31 | €800.01 Million ≈ $935.29 Million |
+361.31% |
| 2019-12-31 | €173.42 Million ≈ $202.75 Million |
+85.33% |
| 2018-12-31 | €93.58 Million ≈ $109.40 Million |
-- |
About CureVac NV
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRN… Read more